You are here

  • Home
  • Archive
  • Volume 9, Issue 12
  • Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial

Citation Tools

Article menu
Oncolytic and local immunotherapy
Original research
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Moreno V, Barretina-Ginesta M, García-Donas J, et al
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
Journal for ImmunoTherapy of Cancer 2021;9:e003645. doi: 10.1136/jitc-2021-003645